高迁移率族蛋白B1在脂多糖诱导急性肺损伤/急性呼吸窘迫综合征中的作用机制
该研究在小鼠脂多糖诱导ALI/ARDS模型及人脐静脉内皮细胞中探讨HMGB1的作用。小鼠腹腔注射20 mg/kg脂多糖造模,EP治疗组腹腔注射40 mg/kg HMGB1抑制剂丙酮酸乙酯。结果显示,与ALI/ARDS模型组相比,EP治疗组肺组织HS和SDC-1表达显著升高、HPA和MMP-9表达显著降低,血清HMGB1含量显著降低(131.88±16.67 μg/L vs. 341.13±22.47 μg/L,P<0.05)。体外实验显示,与HMGB1组相比,HMGB1+EP组HS和SDC-1表达显著升高、HPA和MMP-9表达显著降低。作者认为HMGB1参与脂多糖诱导的内皮细胞糖萼损伤,导致肺通透性增加,抑制HMGB1可减轻肺损伤。
要点
- 小鼠腹腔注射20 mg/kg脂多糖建立ALI/ARDS模型,6小时后取材检测肺组织及血清指标。
- EP治疗组较ALI/ARDS模型组肺组织HS和SDC-1表达显著升高(HS:0.80±0.20 vs. 0.53±0.02;SDC-1:0.72±0.02 vs. 0.51±0.01,均P<0.05)。
- EP治疗组较ALI/ARDS模型组肺组织HPA和MMP-9表达显著降低(HPA:2.36±0.05 vs. 3.00±0.04;MMP-9:2.55±0.13 vs. 3.26±0.05,均P<0.05),血清HMGB1显著降低(131.88±16.67 μg/L vs. 341.13±22.47 μg/L,P<0.05)。
- 体外HMGB1+EP组较HMGB1组HS和SDC-1表达显著升高(HS:0.83±0.07 vs. 0.56±0.03;SDC-1:0.80±0.01 vs. 0.61±0.01,均P<0.05),HPA和MMP-9表达显著降低(HPA:1.30±0.02 vs. 2.29±0.05;MMP-9:1.55±0.04 vs. 2.50±0.06,均P<0.05)。
- 作者认为HMGB1参与脂多糖诱导的内皮细胞糖萼损伤,导致肺通透性增加,抑制HMGB1可减轻肺损伤。
适用人群与场景
- 体内实验:24只SPFC57BL/6雄性小鼠,随机分为正常对照组、ALI/ARDS模型组、丙酮酸乙酯治疗组和丙酮酸乙酯对照组,每组6只。
- 体外实验:人脐静脉内皮细胞(HUVECs),随机分为6组:正常对照组、HUVECs损伤组、HMGB1组、HMGB1+EP组、LPS+EP组、EP组。
处置流程与药物剂量
- 小鼠ALI/ARDS模型:腹腔注射20 mg/kg脂多糖建立模型。
- 正常对照组和丙酮酸乙酯对照组:腹腔注射等量无菌生理盐水。
- 丙酮酸乙酯治疗组和丙酮酸乙酯对照组:腹腔注射40 mg/kg HMGB1抑制剂丙酮酸乙酯;6小时后处死小鼠取材。
- 体外HUVECs损伤组:1 mg/L脂多糖处理6小时。
- 体外HMGB1组:1 μmol/L重组HMGB1处理6小时。
- 体外HMGB1+EP组:重组HMGB1处理1小时后加入1 μmol/L丙酮酸乙酯处理6小时。
- 体外LPS+EP组:脂多糖处理1小时后加入1 μmol/L丙酮酸乙酯处理6小时。
- 体外EP组:1 μmol/L丙酮酸乙酯处理6小时。
研究设计与关键结果
- 体内实验光镜下可见脂多糖刺激后肺泡间隔增厚,肺泡腔内大量炎症细胞浸润。
- 与ALI/ARDS模型组相比,EP治疗组肺组织HS和SDC-1表达显著升高(HS荧光强度:0.80±0.20 vs. 0.53±0.02;SDC-1荧光强度:0.72±0.02 vs. 0.51±0.01,均P<0.05),HPA和MMP-9表达显著降低(HPA荧光强度:2.36±0.05 vs. 3.00±0.04;MMP-9荧光强度:2.55±0.13 vs. 3.26±0.05,均P<0.05);EP对照组上述指标无显著变化。
- 与ALI/ARDS模型组相比,EP治疗组血清HMGB1含量显著降低(μg/L:131.88±16.67 vs. 341.13±22.47,P<0.05);EP对照组无显著变化。
- 体外实验中,与HMGB1组相比,HMGB1+EP组HS和SDC-1表达显著升高(HS荧光强度:0.83±0.07 vs. 0.56±0.03;SDC-1荧光强度:0.80±0.01 vs. 0.61±0.01,均P<0.05),HPA和MMP-9表达显著降低(HPA荧光强度:1.30±0.02 vs. 2.29±0.05;MMP-9荧光强度:1.55±0.04 vs. 2.50±0.06,均P<0.05);EP组HS、SDC-1、HPA和MMP-9表达无显著变化。
证据类型、等级与局限
- 证据类型:动物实验与体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HMGB1参与脂多糖诱导的内皮细胞糖萼损伤,导致肺通透性增加,抑制HMGB1可减轻肺损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the role and possible pathogenesis of high mobility group protein B1 (HMGB1) in lipopolysaccharide (LPS)-induced acute lung injury/acute respiratory distress syndrome (ALI/ARDS).
METHODS: (1) In vivo, 24 SPFC57BL/6 male mice were randomly divided into normal control group, ALI/ARDS model group, ethyl pyruvate (EP) treatment group and EP control group, with 6 mice in each group. The ALI/ARDS model was established by intraperitoneal injection of 20 mg/kg LPS. Mice in normal control group and EP control group were intraperitoneally injected with the same amount of sterile normal saline. Then, mice in the EP treatment group and EP control group were intraperitoneally injected with 40 mg/kg HMGB1 inhibitor EP. After 6 hours, the mice were sacrificed and lung tissues were collected. The expressions of heparan sulfate (HS), syndecans-1 (SDC-1), heparanase (HPA) and matrix metalloproteinases-9 (MMP-9) in lung tissues were detected by immunofluorescence technique. Orbital blood of mice was collected and serum was extracted to detect the content of HMGB1 by enzyme linked immunosorbent assay (ELISA). (2) In vitro, human umbilical vein endothelial cells (HUVECs) were randomly divided into 6 groups: normal control group, HUVECs damage group (treated with 1 mg/L LPS for 6 hours), HMGB1 group (treated with 1 μmol/L recombinant HMGB1 for 6 hours), HMGB1+EP group (treated with recombinant HMGB1 for 1 hour and then added 1 μmol/L EP for 6 hours), LPS+EP group (treated with LPS for 1 hour and then added 1 μmol/L EP for 6 hours), EP group (treated with 1 μmol/L EP for 6 hours). The expressions of HS, SDC-1, HPA and MMP-9 in endothelial cells were detected by immunofluorescence technique.
RESULTS: (1) In vivo, light microscopy showed that the alveolar space was thickened after LPS stimulation, and there were a large number of inflammatory cells infiltrating in the alveolar space. Compared with ALI/ARDS model group, the expressions of HS and SDC-1 in lung tissue of EP treatment group were significantly increased [HS (fluorescence intensity): 0.80±0.20 vs. 0.53±0.02, SDC-1 (fluorescence intensity): 0.72±0.02 vs. 0.51±0.01, both P < 0.05], and the expressions of HPA and MMP-9 were significantly decreased [HPA (fluorescence intensity): 2.36±0.05 vs. 3.00±0.04, MMP-9 (fluorescence intensity): 2.55±0.13 vs. 3.26±0.05, both P < 0.05]; there were no significant changes of the above indexes in EP control group. Compared with ALI/ARDS model group, the content of serum HMGB1 in EP treatment group decreased significantly (μg/L: 131.88±16.67 vs. 341.13±22.47, P < 0.05); there was no significant change in the EP control group. (2) In vitro, compared with HMGB1 group, the expressions of HS and SDC-1 in HMGB1+EP group were significantly higher [HS (fluorescence intensity): 0.83±0.07 vs. 0.56±0.03, SDC-1 (fluorescence intensity): 0.80±0.01 vs. 0.61±0.01, both P < 0.05], and the expressions of HPA and MMP-9 were significantly lower [HPA (fluorescence intensity): 1.30±0.02 vs. 2.29±0.05, MMP-9 (fluorescence intensity): 1.55±0.04 vs. 2.50±0.06, both P < 0.05]; the expression of HS, SDC-1, HPA and MMP-9 had no significant changes in EP group.
CONCLUSIONS: HMGB1 participates in LPS-induced injury of endothelial cell glycocalyx, leading to increased lung permeability, and inhibition of HMGB1 can alleviate lung injury.
参考来源
- Qu J, Feng J, Li J, et al. [Mechanism of high mobility group protein B1 in lipopolysaccharide-induced acute lung injury/acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36177925. doi:10.3760/cma.j.cn121430-20220308-00224
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。